Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BiomX ( (PHGE) ) has provided an update.
On June 9, 2025, BiomX Inc. released an updated corporate presentation highlighting their progress in phage therapy, a promising solution for antibiotic-resistant infections. The presentation showcased positive clinical trial results, including Phase 2 data for S. aureus infections and Phase 1b/2a data for P. aeruginosa infections, indicating significant advancements in treatment efficacy and safety. This development positions BiomX as a leader in addressing the critical threat of antimicrobial resistance, with potential implications for stakeholders in the healthcare sector.
The most recent analyst rating on (PHGE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing phage therapy solutions to combat antibiotic-resistant infections. Their primary products target persistent infections such as those caused by S. aureus and P. aeruginosa, with a market focus on addressing the urgent global healthcare challenge of antibiotic resistance.
Average Trading Volume: 121,544
Technical Sentiment Signal: Sell
Current Market Cap: $12.28M
Learn more about PHGE stock on TipRanks’ Stock Analysis page.